Brainclinics was founded in 2001 as an independent research institute by dr. Martijn Arns and specializes in advancing our understanding of the brain. The results of our research are a valuable aid in the treatment and prevention of symptoms such as mood-, concentration-, impulse control-, and sleep problems, often seen in disorders such as depression, ADHD, and insomnia. Over the last 20 years, Brainclinics has pioneered the application of neurofeedback in the treatment of ADHD and insomnia, was one of the first to recognize the importance of the circadian clock and sleep problems underlying many symptoms like impaired concentration and impulse control, specifically in ADHD, while also pioneering and refining magnetic brain stimulation (rTMS) in the treatment of depression and obsessive–compulsive disorder (OCD). In 2019 the legal structure was changed, and the non-profit Brainclinics Foundation was established. The Brainclinics Foundation’s primary mission is best summarized as: Applied Neuroscience from the clinic, to the clinic. Therefore, the two pillars of the foundation are formed by Research Institute Brainclinics and Brainclinics Insights (the publishing division).

At Research Institute Brainclinics researchers have published over 170 scientific publications on these and related topics and continue to collaborate with researchers and universities around the world ranging from Australia, Germany, Belgium, the United States to Colombia. A key topic of our research revolves around ‘personalized medicine’, going beyond the traditional ‘diagnostic-thinking’ and focusing on individual differences that can help optimize and individualize treatment and prevent symptoms from occurring. Our research has resulted in 4 patents and several spin-offs, such as Brainquiry, where the first ever wireless Bluetooth based EEG amplifier was developed in 2003 and the first wrist-worn heart-rate device in 2005 (nine years before Apple launched the Apple Watch with similar technology). Other spin-offs are Brainclinics Education, where specialistic applied neuroscience training courses were developed focused on rTMS, neurofeedback and QEEG, and Brainclinics Treatment, where our unequalled knowledge and expertise on personalized neuromodulation treatments are applied to benefit people worldwide. In 2015, Brainclinics Education and Brainclinics Treatment were acquired by the neuroCare Group, where courses are still taught by neuroCademy, and neuromodulation treatments that followed from Brainclinics Research are offered in >15 neuroCare clinics worldwide.

Brainclinics Insights is the publishing division of our foundation. Its mission is to make the knowledge, expertise and especially ‘Insights’ gained through our research, widely available through books, PhD theses and interactive media.

To serve the goal of the Brainclinics Foundation, all proceeds are fully invested into Research Institute Brainclinics and Brainclinics Insights, which creates an unprecedented synergy between these divisions and makes it possible to perform research and share new future insights as well.

At the Brainclinics Foundation, it is all about the research and its application!

#Slaap2019 'De zin en onzin van melatonine voorschrijven'. Consensus: Begin altijd met gedrag, CGT-I, combineer zo nodig met lichttherapie. Melatonine kan effect hebben bij DSPD, gebruik als chronobioticum. Bij kinderen helpt als personalized Medicine soms melatonine (0,2-0,5 mg)

Wake up! Het belang van slaapdiagnostiek in de GGZ - #eLearning (1 PE punt) door o.a. Martijn Arns van @Brainclinics . Lees hier de korte samenvatting: http://bit.ly/304q1BN

Today Brainclinics Foundation signed a collaborative agreement with @SynaedaPMC to further develop personalized care in depression through applied neuroscience!

Just published: EEG Characteristics of Suicidal Behavior in Female Patients With Major Depressive Disorder
A potential biomarker to predict suicide risk?

This #map might do your head in. Difference between solar and standard time. Source: https://www.reddit.com/r/MapPorn/comments/9kbbwb/how_much_time_is_wrong_around_the_world/?st=JMQ0IN2A&sh=39917a9d

Wie komt ons onderzoeksteam versterken?
Vacature: Research Assistant/PhD Candidate QEEG Biomarker onderzoek bij depressie (24-32 uur p/week) in samenwerking met Synaeda.
Sluitingsdatum 11 november.

Just published: Cardiovascular effects of iTBS; further validation of NCG-TMS. Prefrontal iTBS resulted in trans-synaptic activation of parasympathetic branch, lower HR, increased HRV and lower BP!
Thanks @NinetLab for great collaboration!

Could #biomarkers help predict acute #suicide risk? This #EEG study investigated whether #MDD patients with suicidal attempts or ideation have unique spatial-frequency power characteristics. http://bit.ly/2JxNCVE @ugent @TUeindhoven @Brainclinics @UniUtrecht @neuroCareGroup

Load More...